Dotin

Dotinurad is indicated for the treatment of gout and hyperuricemia.

Dotinurad is a URAT1-selective urate reabsorption inhibitor that selectively inhibits URAT1 and inhibits urate reabsorption, thereby increasing urinary urate excretion and lowering serum urate levels. In addition, since it has weak inhibitory effects on ABCG2, OAT1 and OAT3 other than URAT143,44, it is expected to effectively lower serum uric acid levels without affecting uric acid secretion via these transporters. Thus, Dotinurad is a selective urate reabsorption inhibitor (SURI) that inhibits the reabsorption pathway mediated by URAT1 without inhibiting the uric acid secretion pathway mediated by ABCG2, OAT1 and OAT3 because of its high URAT1 selectivity.

The most commonly reported side effects gouty arthritis, limb discomfort (1% to less than 5%). (Loose stools, increased y-GTP, arthralgia, kidney stones, nephrocalcinosis, increased urinary y2 macroglobulin, increased blood creatinine, increased urine albumin/creatinine ratio, positive urine albumin) has been reported in less than 1% patients.

During pregnancy, Dotinurad should only be treated if the therapeutic benefits are judged to outweigh the risks. This drug is excreted in breast milk. Consult your doctor before breastfeeding.

Gouty Arthritis: This drug is a uric acid-lowering drug and lowering the blood uric acid level at the onset of gouty arthritis (gouty attack) may exacerbate gouty arthritis (gouty attack). If gouty arthritis (gout attack) is observed before administration of this drug, administration of this drug should not be started until the symptoms subside. In addition, if gouty arthritis (gouty attack) occurs during administration of this drug, administration should be continued without changing the dose of this drug and colchicine, non-steroidal anti-inflammatory drugs, corticosteroids etc. may be administered depending on the symptoms. Use together.

Patients with urolithiasis: Do not administer unless it is judged to be unavoidable for treatment. The pharmacological action of this drug may exacerbate the symptoms of urinary calculi due to increased urinary uric acid excretion.

Patients with renal impairment: Consider treatment with other agents. Since this drug acts in the renal proximal tubule, its efficacy may be reduced depending on the degree of renal dysfunction. In particular, administration of this drug should be avoided in patients with oliguria or anuria, as its efficacy cannot be expected.

Patients with hepatic impairment: Careful follow-up should be performed. Serious liver damage has been observed with other uricosuric agents.

Drugs used in Gout, Urate reabsorption inhibitor